1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Fecal Calprotectin Test Market
4. Market Overview
    4.1. Introduction
        4.1.1. Patient Type Definition
        4.1.2. Industry Evolution / Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Fecal Calprotectin Test Market Analysis and Forecast, 2017-2031
        4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
    5.1. Technological Advancement
    5.2. Diseases Epidemiology
    5.3. Regulatory Scenario
    5.4. Pricing Analysis
    5.5. COVID-19 Impact Analysis
6. Global Fecal Calprotectin Test Market Analysis and Forecast, by Patient Type
    6.1. Introduction & Definition
    6.2. Key Findings / Developments
    6.3. Market Value Forecast, by Patient Type, 2017-2031
        6.3.1. Adult
        6.3.2. Pediatric
    6.4. Market Attractiveness Analysis, by Patient Type
7. Global Fecal Calprotectin Test Market Analysis and Forecast, by Assay Type
    7.1. Introduction & Definition
    7.2. Key Findings / Developments
    7.3. Market Value Forecast, by Assay Type, 2017-2031
        7.3.1. ELISA (Enzyme linked Immunosorbent Assay)
        7.3.2. Enzyme Fluoroimmunoassay
        7.3.3. Quantitative Immune-chromatography
    7.4. Market Attractiveness Analysis, by Assay Type
8. Global Fecal Calprotectin Test Market Analysis and Forecast, by Indication
    8.1. Introduction & Definition
    8.2. Key Findings / Developments
    8.3. Market Value Forecast, by Indication, 2017-2031
        8.3.1. Inflammatory Bowel Disease
        8.3.2. Colorectal Cancer
        8.3.3. Celiac Disease
    8.4. Market Attractiveness Analysis, by Indication
9. Global Fecal Calprotectin Test Market Analysis and Forecast, by End-user
    9.1. Introduction & Definition
    9.2. Key Findings / Developments
    9.3. Market Value Forecast, by End-user, 2017-2031
        9.3.1. Hospitals
        9.3.2. Diagnostic Laboratories
        9.3.3. Academic & Research Institutes
    9.4. Market Attractiveness Analysis, by End-user
10. Global Fecal Calprotectin Test Market Analysis and Forecast, by Region
    10.1. Key Findings
    10.2. Market Value Forecast, by Region
        10.2.1. North America
        10.2.2. Europe
        10.2.3. Asia Pacific
        10.2.4. Latin America
        10.2.5. Middle East & Africa
    10.3. Market Attractiveness Analysis, by Region
11. North America Fecal Calprotectin Test Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Patient Type, 2017-2031
        11.2.1. Adult
        11.2.2. Pediatric
    11.3. Market Value Forecast, by Assay Type, 2017-2031
        11.3.1. ELISA (Enzyme linked Immunosorbent Assay)
        11.3.2. Enzyme Fluoroimmunoassay
        11.3.3. Quantitative Immune-chromatography
    11.4. Market Value Forecast, by Indication, 2017-2031
        11.4.1. Inflammatory Bowel Disease
        11.4.2. Colorectal Cancer
        11.4.3. Celiac Disease
    11.5. Market Value Forecast, by End-user, 2017-2031
        11.5.1. Hospitals
        11.5.2. Diagnostic Laboratories
        11.5.3. Academic & Research Institutes
    11.6. Market Value Forecast, by Country, 2017-2031
        11.6.1. U.S.
        11.6.2. Canada
    11.7. Market Attractiveness Analysis
        11.7.1. By Patient Type
        11.7.2. By Assay Type
        11.7.3. By Indication
        11.7.4. By End-user
        11.7.5. By Country
12. Europe Fecal Calprotectin Test Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Patient Type, 2017-2031
        12.2.1. Adult
        12.2.2. Pediatric
    12.3. Market Value Forecast, by Assay Type, 2017-2031
        12.3.1. ELISA (Enzyme linked Immunosorbent Assay)
        12.3.2. Enzyme Fluoroimmunoassay
        12.3.3. Quantitative Immune-chromatography
    12.4. Market Value Forecast, by Indication, 2017-2031
        12.4.1. Inflammatory Bowel Disease
        12.4.2. Colorectal Cancer
        12.4.3. Celiac Disease
    12.5. Market Value Forecast, by End-user, 2017-2031
        12.5.1. Hospitals
        12.5.2. Diagnostic Laboratories
        12.5.3. Academic & Research Institutes
    12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        12.6.1. Germany
        12.6.2. U.K.
        12.6.3. France
        12.6.4. Italy
        12.6.5. Spain
        12.6.6. Rest of Europe
    12.7. Market Attractiveness Analysis
        12.7.1. By Patient Type
        12.7.2. By Assay Type
        12.7.3. By Indication
        12.7.4. By End-user
        12.7.5. By Country/Sub-region
13. Asia Pacific Fecal Calprotectin Test Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Patient Type, 2017-2031
        13.2.1. Adult
        13.2.2. Pediatric
    13.3. Market Value Forecast, by Assay Type, 2017-2031
        13.3.1. ELISA (Enzyme linked Immunosorbent Assay)
        13.3.2. Enzyme Fluoroimmunoassay
        13.3.3. Quantitative Immune-chromatography
    13.4. Market Value Forecast, by Indication, 2017-2031
        13.4.1. Inflammatory Bowel Disease
        13.4.2. Colorectal Cancer
        13.4.3. Celiac Disease
    13.5. Market Value Forecast, by End-user, 2017-2031
        13.5.1. Hospitals
        13.5.2. Diagnostic Laboratories
        13.5.3. Academic & Research Institutes
    13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        13.6.1. China
        13.6.2. Japan
        13.6.3. India
        13.6.4. Australia & New Zealand
        13.6.5. Rest of Asia Pacific
    13.7. Market Attractiveness Analysis
        13.7.1. By Patient Type
        13.7.2. By Assay Type
        13.7.3. By Indication
        13.7.4. By End-user
        13.7.5. By Country/Sub-region
14. Latin America Fecal Calprotectin Test Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Patient Type, 2017-2031
        14.2.1. Adult
        14.2.2. Pediatric
    14.3. Market Value Forecast, by Assay Type, 2017-2031
        14.3.1. ELISA (Enzyme linked Immunosorbent Assay)
        14.3.2. Enzyme Fluoroimmunoassay
        14.3.3. Quantitative Immune-chromatography
    14.4. Market Value Forecast, by Indication, 2017-2031
        14.4.1. Inflammatory Bowel Disease
        14.4.2. Colorectal Cancer
        14.4.3. Celiac Disease
    14.5. Market Value Forecast, by End-user, 2017-2031
        14.5.1. Hospitals
        14.5.2. Diagnostic Laboratories
        14.5.3. Academic & Research Institutes
    14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        14.6.1. Brazil
        14.6.2. Mexico
        14.6.3. Rest of Latin America
    14.7. Market Attractiveness Analysis
        14.7.1. By Patient Type
        14.7.2. By Assay Type
        14.7.3. By Indication
        14.7.4. By End-user
        14.7.5. By Country/Sub-region
15. Middle East & Africa Fecal Calprotectin Test Market Analysis and Forecast
    15.1. Introduction
        15.1.1. Key Findings
    15.2. Market Value Forecast, by Patient Type, 2017-2031
        15.2.1. Adult
        15.2.2. Pediatric
    15.3. Market Value Forecast, by Assay Type, 2017-2031
        15.3.1. ELISA (Enzyme linked Immunosorbent Assay)
        15.3.2. Enzyme Fluoroimmunoassay
        15.3.3. Quantitative Immune-chromatography
    15.4. Market Value Forecast, by Indication, 2017-2031
        15.4.1. Inflammatory Bowel Disease
        15.4.2. Colorectal Cancer
        15.4.3. Celiac Disease
    15.5. Market Value Forecast, by End-user, 2017-2031
        15.5.1. Hospitals
        15.5.2. Diagnostic Laboratories
        15.5.3. Academic & Research Institutes
    15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        15.6.1. GCC Countries
        15.6.2. South Africa
        15.6.3. Rest of Middle East & Africa
    15.7. Market Attractiveness Analysis
        15.7.1. By Patient Type
        15.7.2. By Assay Type
        15.7.3. By Indication
        15.7.4. By End-user
        15.7.5. By Country/Sub-region
16. Competition Landscape
    16.1. Market Player – Competitive Matrix (by tier and size of companies)
    16.2. Market Share Analysis, by Company (2022)
    16.3. Company Profiles
        16.3.1. Abbexa
            16.3.1.1. Company Overview
            16.3.1.2. Drug Class Portfolio
            16.3.1.3. SWOT Analysis
            16.3.1.4. Financial Overview
            16.3.1.5. Strategic Overview
        16.3.2. ALPCO
            16.3.2.1. Company Overview
            16.3.2.2. Drug Class Portfolio
            16.3.2.3. SWOT Analysis
            16.3.2.4. Financial Overview
            16.3.2.5. Strategic Overview
        16.3.3. Alpha Laboratories
            16.3.3.1. Company Overview
            16.3.3.2. Drug Class Portfolio
            16.3.3.3. SWOT Analysis
            16.3.3.4. Financial Overview
            16.3.3.5. Strategic Overview
        16.3.4. Biomerica
            16.3.4.1. Company Overview
            16.3.4.2. Drug Class Portfolio
            16.3.4.3. SWOT Analysis
            16.3.4.4. Financial Overview
            16.3.4.5. Strategic Overview
        16.3.5. BÜHLMANN Laboratories AG
            16.3.5.1. Company Overview
            16.3.5.2. Drug Class Portfolio
            16.3.5.3. SWOT Analysis
            16.3.5.4. Financial Overview
            16.3.5.5. Strategic Overview
        16.3.6. DRG Instruments GmbH
            16.3.6.1. Company Overview
            16.3.6.2. Drug Class Portfolio
            16.3.6.3. SWOT Analysis
            16.3.6.4. Financial Overview
            16.3.6.5. Strategic Overview
        16.3.7. EagleBio
            16.3.7.1. Company Overview
            16.3.7.2. Drug Class Portfolio
            16.3.7.3. SWOT Analysis
            16.3.7.4. Financial Overview
            16.3.7.5. Strategic Overview
        16.3.8. Epitope Diagnostics, Inc.
            16.3.8.1. Company Overview
            16.3.8.2. Drug Class Portfolio
            16.3.8.3. SWOT Analysis
            16.3.8.4. Financial Overview
            16.3.8.5. Strategic Overview
        16.3.9. OPERON, S.A.
            16.3.9.1. Company Overview
            16.3.9.2. Drug Class Portfolio
            16.3.9.3. SWOT Analysis
            16.3.9.4. Financial Overview
            16.3.9.5. Strategic Overview
        16.3.10. R-Biopharm AG
            16.3.10.1. Company Overview
            16.3.10.2. Drug Class Portfolio
            16.3.10.3. SWOT Analysis
            16.3.10.4. Financial Overview
            16.3.10.5. Strategic Overview
        16.3.11. Svar Life Science
            16.3.11.1. Company Overview
            16.3.11.2. Drug Class Portfolio
            16.3.11.3. SWOT Analysis
            16.3.11.4. Financial Overview
            16.3.11.5. Strategic Overview
        16.3.12. Thermo Fisher Scientific, Inc.
            16.3.12.1. Company Overview
            16.3.12.2. Drug Class Portfolio
            16.3.12.3. SWOT Analysis
            16.3.12.4. Financial Overview
            16.3.12.5. Strategic Overview
        16.3.13. Werfen
            16.3.13.1. Company Overview
            16.3.13.2. Drug Class Portfolio
            16.3.13.3. SWOT Analysis
            16.3.13.4. Financial Overview
            16.3.13.5. Strategic Overview
        16.3.14. SENTINEL CH. SpA
            16.3.14.1. Company Overview
            16.3.14.2. Drug Class Portfolio
            16.3.14.3. SWOT Analysis
            16.3.14.4. Financial Overview
            16.3.14.5. Strategic Overview
        16.3.15. Diazyme Laboratories, Inc.
            16.3.15.1. Company Overview
            16.3.15.2. Drug Class Portfolio
            16.3.15.3. SWOT Analysis
            16.3.15.4. Financial Overview
            16.3.15.5. Strategic Overview
        16.3.16. DiAgam
            16.3.16.1. Company Overview
            16.3.16.2. Drug Class Portfolio
            16.3.16.3. SWOT Analysis
            16.3.16.4. Financial Overview
            16.3.16.5. Strategic Overview
Table 01: Global Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Patient Type, 2017-2031
Table 02: Global Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Assay Type, 2017-2031
Table 03: Global Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 04: Global Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 05: Global Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 06: North America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 07: North America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Patient Type, 2017-2031
Table 08: North America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Assay Type, 2017-2031
Table 09: North America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 10: North America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 11: Europe Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 12: Europe Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Patient Type, 2017-2031
Table 13: Europe Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Assay Type, 2017-2031
Table 14: Europe Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 15: Europe Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 16: Asia Pacific Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 17: Asia Pacific Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Patient Type, 2017-2031
Table 18: Asia Pacific Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Assay Type, 2017-2031
Table 19: Asia Pacific Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 20: Asia Pacific Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 21: Latin America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 22: Latin America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Patient Type, 2017-2031
Table 23: Latin America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Assay Type, 2017-2031
Table 24: Latin America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 25: Latin America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 26: Middle East & Africa Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 27: Middle East & Africa Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
Table 28: Middle East & Africa Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Assay Type, 2017-2031
Table 29: Middle East & Africa Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 30: Middle East & Africa Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by End-user, 2017-2031
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer


-gr.jpg)